🚀 Medial Secures Investment on Shark Tank India - Fueling the Future of Professional Social Networking. 🔥
Login

News on Medial

Related News

Dozen debuts in mutual fund's July portfolio: Check out the stocks and suitors

Money ControlMoney Control · 11m ago
Dozen debuts in mutual fund's July portfolio: Check out the stocks and suitors
Medial

Mutual funds have shown active investment in newly-listed companies' anchor books in addition to bidding in initial public offerings (IPOs). In July, significant mutual fund investments were made in Emcure Pharmaceuticals, Bansal Wire Industries, and Pearl Global Industries. Emcure Pharmaceuticals received the highest investment, with mutual funds purchasing 6.59 million shares worth Rs 860 crore. Other newly-listed companies that attracted mutual fund investments include Akums Drugs & Pharma, Entero Healthcare Solutions, Sanstar, and R Systems International. In contrast, mutual funds exited positions in Vascon Engineering, Borosil Scientific, Siyaram Silk Mills, and Shilchar Technologies.

Akumentis Healthcare income crosses Rs 400 Cr in FY24; posts Rs 57 Cr profit

EntrackrEntrackr · 1y ago
Akumentis Healthcare income crosses Rs 400 Cr in FY24; posts Rs 57 Cr profit
Medial

Pharmaceutical company Akumentis Healthcare has reported a flat scale during the last fiscal year ending March 2024. However, the controlled cost mechanism helped the Thane-based firm to improve its margins and bottom line during the same period. Akumentis Healthcare saw a modest 2.8% increase in its scale to Rs 398 crore in FY24 from Rs 387 crore in FY23, its standalone financial statements filed with the Registrar of Companies show. *Note: Akumentis Healthcare is a wholly-owned subsidiary of Akum Drugs and Pharma Ltd which recorded a 14.3% increase in revenue to Rs 4,178 crore in FY24 from Rs 3,655 crore in FY23. Founded in 2010, Akumentis Healthcare provides medicinal products including creams and medicines across dermatology, orthopedics, gynecology, critical care, cardiovascular, diabetes, and pediatrics. The sale of these products was the sole source of revenue for the company. Akumentis made Rs 10 crore from interest and other miscellaneous sources tallying its overall income to Rs 409 crore in FY24. When it comes to burn, around 36.6% (Rs 122 crore) of its total burn went to employee benefits while cost of material consumed 31.5% (Rs 105 crore) of the overall expenditure in FY24. Its marketing (advertising cum promotion), commission paid to selling agents, traveling, legal and other overheads took Akumentis’ total expenditure to Rs 333 crore in FY24 from Rs 340 crore in FY23. Check TheKredible for more details. The controlled spending on employee benefits and related expenses helped Akumentis Healthcare increase its margins. As a result, the firm’s profit spiked 62.9% to Rs 57 crore in FY24 from Rs 35 crore in FY23. Its ROCE and EBITDA margin improved to 57.46% and 62.90%, respectively. On a unit level, Akumentis spent Rs 0.84 to earn a rupee. FY23-FY24 FY23 FY24 EBITDA Margin 19.26% 62.90% Expense/₹ of Op Revenue ₹0.88 ₹0.84 ROCE 65.38 57.46 Rajaram Samant, who was the co-founder and chief executive officer of Akumentis Healthcare for nearly 10 years, left the company in February 2020. Samant had previously worked at three large public companies: Ranbaxy, Emcure and Wanbury. In 2015, Peak XV had led a $19 million round in Akumentis.

PB Healthcare to raise Rs 1,461 Cr in seed round; no longer subsidiary of PB Fintech

EntrackrEntrackr · 2m ago
PB Healthcare to raise Rs 1,461 Cr in seed round; no longer subsidiary of PB Fintech
Medial

PB Healthcare Services, formerly a wholly-owned subsidiary of PB Fintech Limited, is raising Rs 1,461 crore (approximately $171 million) as part of the first tranche of its seed round. Of the total amount, Rs 539.4 crore has already been infused by PB Fintech Limited, while the remaining capital will be contributed by external investors, according to disclosures filed with the National Stock Exchange (NSE). For context, PB Fintech had earlier passed a resolution to invest up to Rs 696 crore through the purchase of equity shares or preference shares of PB Healthcare Services Private Limited in FY26. As part of the current round, it has already invested Rs 539.4 crore, with the remaining amount yet to be deployed. As per the filings, PB Fintech’s stake in PB Healthcare Services has dropped from 100% to 32.14% following the participation of external investors in the seed round. Previously a wholly-owned subsidiary, PB Healthcare has also created an ESOP pool to attract and retain key talent. The capital infusion is aimed at strengthening the company’s financial position and supporting its growth plans. “The dilution in shareholding is a strategic decision to bring in external investors and create an ESOP pool to attract and retain talent,” the company noted in its filing. Founded in January 2025, PB Healthcare Services set out with an ambitious goal of establishing hospitals with a cumulative capacity of 1,000 beds within its first year. The company plans to launch operations in the National Capital Region (NCR), with a phased expansion into other major metro cities.

Download the medial app to read full posts, comements and news.